Expressions of biomarkers in MCF7 Breast and Colon Cancer Cell Lines
Cancer is one of the leading causes of death which accounts for 13% of total deaths, worldwide. Colorectal and Breast cancer fall under main categories according to World Health Organisation (WHO) cancer facts sheet 1. The need to understand the expression of clinical biomarkers in breast cancer and colon cancer is necessary for diagnosis and therapeutic response. In this article, the expressions of histone H1 and TP53 biomarkers were established for four different colon cancer cell lines and compared with the expressions of MCF7 cell line. The results show varied expression of Histone H1 along with TP53 markers among the cell lines. The results suggest that the linker Histone H1 has shown nuclear localization in HCT 116p53 wt (wild type) cancer cell line whereas it has shown cytoplasmic distribution in the respective null type cell line with intense expression. The result also suggests that a localized distribution in HRA19 cells and a diffused distribution in SNU-C2B cell line. These established results were compared with the expression of the biomarkers in MCF7 in order to get a better understanding.
Keywords: Tumour Proteins, p53, H1, MCF-7 cell, HCT116, HRA19.
2. Nicolas Goossens, Shigeki Nakagawa, Xiaochen Sun, Yujin Hoshida. Cancer biomarker discovery and validation. Transl Cancer Res. 2015 June; 4(3):256–269.
3. Caroline Rocha de Oliveira Lima , Rogério Elias Rabelo ,Valcinir Aloísio Scalla Vulcani , Lorena Damasio Cardoso , Nicaelle Luan de Moura Sousa , Veridiana Maria Brianezi Dignani de Moura. P53 gene: major mutations in neoplasias and anticancer gene therapy. 2012; Cienc.Rural 42 (5).
4. Noa Rivlin, Ran Brosh, Moshe Oren, and Varda Rotter Mutations in the p53 Tumor Suppressor Gene Important Milestones at the Various Steps of Tumorigenesis Genes Cancer. 2011 Apr; 2(4): 466–474.
5. Guohong Li and Danny Reinberg Chromatin higher-order structures and gene regulation. Curr Opin Genet Dev. 2011 Apr; 21(2):175–186.
6. Steven Henikoff and M. Mitchell Smith. Histone Variants and Epigenetics. Cold Spring Harb Perspect Biol. 2015 Jan; 7(1):a019364.
7. Serban Comsa, Anca Maria, Cimpean, Marius Raica. The Story of MCF-7 Breast Cancer Cell Line: 40 years of Experience in Research. Anticancer Research June 2015; 35:63147-3154
8. Hassan Dana, Ghanbar Mahmoodi Chalbatani, Habibollah Mahmoodzadeh, Rezvan Karimloo, Omid Rezaiean, Amirreza Moradzadeh, Narges Mehmandoost, Fateme Moazzen,Ali Mazraeh, Vahid Marmari, Mohammad Ebrahimi, Mohammad Menati Rashno,Saeid Jan Abadi, and Elahe Gharagouzlo. Molecular Mechanisms and Biological Functions of siRNA. Int J Biomed Sci. 2017; 13(2):48–57.
9. Elledge, R.M., Fuqua, S.A.W., Clark, G.M. et al. The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res Tr 1993; 27:95–102.
10. Seung Wook Kim, Sun Jin Kim, Robert R. Langley, Isaiah J. Fidl. Modulation of the cancer cell transcriptome by culture media formulations and cell density. International journal of oncology; 2015: 46:2067-2075.
12. Yong-Wei Zhang, Rochelle E. Nasto, Sandra A. Jablonski, Ilya G Serebriiskii, Rishi Surana, Joseph Murray, Michael Johnson, Rebecca B. Riggins, Robert Clarke, Erica A. Golemis, Louis M. Weiner. RNA Interference Screening to Identify Proliferation Determinants in Breast Cancer Cells. Bio Protoc. 2017; 7(15). doi:10.21769/BioProtoc.2435.
13. Sean W. Harshman, Michael E. Hoover, Chengsi Huang, Owen E. Branson, Sarah B. Chaney, Carolyn M. Cheney, Thomas J. Rosol, Charles L. Shapiro, Vicki H. Wysocki, Kay Huebner, Michael A. Freitas. Histone H1 Phosphorylation in Breast Cancer. American Chemical Society. J. Proteome Res. 2014; 13:2453−2467.
14. Andrea Izquierdo-Bouldstridge, Alberto Bustillos, Carles Bonet-Costa, Patricia Aribau-Miralbes, Daniel Garc´ıa-Gomis, Marc Dabad, Anna Esteve-Codina, Laura Pascual-Reguant, Sandra Peiro, Manel Esteller, Matthew Murtha, Llu´ıs Millan-Arino, Albert Jordan. Histone H1 depletion triggers an interferon response in cancer cells via activation of heterochromatic repeats. Nucleic Acids Research; 2017:45(20):11622–11642.
15. Vani G , Devi CS. Effect of histone H1 on estrogen receptor status of human breast cancer MCF 7 cells. Mol Cell Biochem. 2005; 272(1-2):151-5.
16. Ye X, Feng C, Gao T, Mu G, Zhu W, Yang Y. Linker Histone in Diseases. Int J Biol Sci 2017; 13(8):1008-1018.
17. Mariana Varna, Guilhem Bousquet, Louis-Francois Plassa, Philippe Bertheau, Anne Janin. TP53 Status and Response to Treatment in Breast Cancers. Review Article. Hindawi Publishing Corporation Journal of Biomedicine and Biotechnology. 2011; 284584.
18. Torres CM, Biran A, Burney MJ, Patel H, Henser-Brownhill T, Cohen AS, Li Y, Ben-Hamo R, Nye E, Spencer-Dene B,Chakravarty P, Efroni S, Matthews N, Misteli T, Meshorer E, Scaffidi P. The linker histone H1.0 generates epigenetic and functional intratumor heterogeneity. Science. 2016 Sep 30; 353(6307). pii: aaf1644.
19. Richard M. Elledge, Suzanne A. W. Fuqua, Gary M. Clark, Pascal Pujol, D. Craig Allred. The role and prognostic significance of p53 gene alterations in breast cancer. Breast Cancer Res Tr 1993; 27:95.
20. Massimo Negrini, Silvia Sabbioni, Subrata Haldar, Laura Possati, Antonella Castagnoli, Alfredo Corallini, Giuseppe Barbanti-Brodano, and Carlo M. Croce. Tumor and Growth Suppression of Breast Cancer Cells by Chromosome 17-associated Functions. Cancer Research; 1994; 54:ISI8-1824.
21. Melissa A Troester, Jason I Herschkowitz, Daniel S Oh, Xiaping He, Katherine A Hoadley,Claire S Barbier, and Charles M Perou. Gene expression patterns associated with p53 status in breast cancer. BMC Cancer. 2006; 6:276.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).